Clinical evaluation of changes in biomarkers by oral intake of NMN

• Material Type: 記事
• Title: Clinical evaluation of changes in biomarkers by oral intake of NMN
• Author/Editor: Yuji Morita; Hiromi Izawa; Atsuyuki Hirano
• Publication, Distribution, etc.: 日本 : 糖化ストレス研究会
• Publication Date: 2022-06-30
• Publication Date (W3CDTF): 2022-06-30
• Alternative Title: NMN経口摂取による各種バイオマーカーの推移についての臨床的評価
• Periodical title: Glycative stress research
• No. or year of volume/issue: 9(2)
• Volume: 9(2)
• ISSN (Periodical Title): 2188-3610
• ISSN-L (Periodical Title): 2188-3610
• Text Language Code: eng; jpn
• DOI: 10.24659/gsr.9.2_33; https://doi.org/10.24659/gsr.9.2_33
• Persistent ID (NDL): info:ndljp/pid/13120768; https://dl.ndl.go.jp/pid/13120768
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• Acquisition Basis: オンライン資料収集制度
• Date Accepted (W3CDTF): 2023-12-08T11:19:22+09:00
• Date Captured (W3CDTF): 2023-05-20
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): https://www.toukastress.jp/webj/page-2
• Periodical Title (Persistent ID (NDL)): info:ndljp/pid/13120767; https://dl.ndl.go.jp/pid/13120767
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• Collection (particular): 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Holding library: 国立国会図書館
• Call No.: Z63-D541
• Related Material (URI): https://dl.ndl.go.jp/info:ndljp/pid/13120768
• Related Material (Persistent ID (NDL)): info:ndljp/pid/13120768; https://dl.ndl.go.jp/info:ndljp/pid/13120768
• Data Provider (Database): 国立国会図書館 : 国立国会図書館雑誌記事索引; https://ndlsearch.ndl.go.jp
• Bibliographic ID (NDL): 032834787; http://id.ndl.go.jp/bib/032834787
• Bibliographic Record Category (NDL): 632

• Summary, etc.: Purpose: The "NAD World" (proposed by Professor Shin-Ichiro Imai of the University of Washington), in which the control of aging, lifespan, and metabolism is systemically integrated through NAD (nicotinamide adenine dinucleotide), has attracted worldwide attention and is being studied from various angles, however, there are few reports of clinical studies in humans. In this study, we investigate the changes in various biomarkers in humans after oral intake of nicotinamide mononucleotide (NMN), a precursor of NAD, and evaluate its clinical significance. Methods: Based on the approval to start the study at the ethics review, 17 postmenopausal women (mean age 55.0 years) without underlying diseases who agreed to participate in the study were subjects and received oral intake of 300 mg/day of pure NMN for eight weeks. The examination items included body measurements, basal metabolic rate, blood pressure, grip strength, glycation level (AF value), blood biochemical tests, various hormones, blood SIRT1 mRNA expression and NMN, NAD and NAM levels, immunological tests (aging, T cell subset including exhausted cells), and skin VAS (visual analog scale). Results were statistically analyzed and compared at zero and eight weeks (blood biochemistry tests were performed at four weeks to confirm safety). In addition, we asked the patients to keep a diary during the course of the study to monitor their NMN intake, their bodily sensation, and side effects. Results: One of the 17 subjects dropped out at the end of four weeks due to persistent mild headache. The results showed significant changes in NAM (nicotinamide/vitamin B3) from 45.2 to 164.7 (p < 0.001), adiponectin from 13.6 to 16.2 (p = 0.004), and skin VAS score (6/7 items, p < 0.001 to = 0.001) before and after intake. Significant differences were also observed for BMI, AF levels, platelets, HbA1c, HDL-C, amylase, DHEA-s, NAD, and narrowly defined regulatory T cells (p < 0.05 above). In addition, all subjects showed a positive bodily sensation with skin, sleep, and fatigue. There were no problems with subjective symptoms or laboratory data in the 16 who completed the study. Conclusion: NMN 300 mg/day orally for eight weeks showed no safety issues and favorable changes in many biomarkers, suggesting that NMN, a member of the NAD world, may be a promising nutritional material for aging and metabolic control in humans.
• DOI: 10.24659/gsr.9.2_33
• Access Restrictions: インターネット公開
• Data Provider (Database): 科学技術振興機構 : J-STAGE; http://www.jstage.jst.go.jp

• Summary, etc.: Purpose: The "NAD World" (proposed by Professor Shin-Ichiro Imai of the University of Washington), in which the control of aging, lifespan, and metabolism is systemically integrated through NAD (nicotinamide adenine dinucleotide), has attracted worldwide attention and is being studied from various angles, however, there are few reports of clinical studies in humans. In this study, we investigate the changes in various biomarkers in humans after oral intake of nicotinamide mononucleotide (NMN), a precursor of NAD, and evaluate its clinical significance. Methods: Based on the approval to start the study at the ethics review, 17 postmenopausal women (mean age 55.0 years) without underlying diseases who agreed to participate in the study were subjects and received oral intake of 300 mg/day of pure NMN for eight weeks. The examination items included body measurements, basal metabolic rate, blood pressure, grip strength, glycation level (AF value), blood biochemical tests, various hormones, blood SIRT1 mRNA expression and NMN, NAD and NAM levels, immunological tests (aging, T cell subset including exhausted cells), and skin VAS (visual analog scale). Results were statistically analyzed and compared at zero and eight weeks (blood biochemistry tests were performed at four weeks to confirm safety). In addition, we asked the patients to keep a diary during the course of the study to monitor their NMN intake, their bodily sensation, and side effects. Results: One of the 17 subjects dropped out at the end of four weeks due to persistent mild headache. The results showed significant changes in NAM (nicotinamide/vitamin B3) from 45.2 to 164.7 (p < 0.001), adiponectin from 13.6 to 16.2 (p = 0.004), and skin VAS score (6/7 items, p < 0.001 to = 0.001) before and after intake. Significant differences were also observed for BMI, AF levels, platelets, HbA1c, HDL-C, amylase, DHEA-s, NAD, and narrowly defined regulatory T cells (p < 0.05 above). In addition, all subjects showed a positive bodily sensation with skin, sleep, and fatigue. There were no problems with subjective symptoms or laboratory data in the 16 who completed the study. Conclusion: NMN 300 mg/day orally for eight weeks showed no safety issues and favorable changes in many biomarkers, suggesting that NMN, a member of the NAD world, may be a promising nutritional material for aging and metabolic control in humans.
• DOI: 10.24659/gsr.9.2_33; https://doi.org/10.24659/gsr.9.2_33
• Related Material (URI): http://id.ndl.go.jp/bib/032834787; https://ndlsearch.ndl.go.jp/books/R000000004-I032834787; https://dl.ndl.go.jp/pid/13120768; http://id.ndl.go.jp/digimeta/13120768; https://search.jamas.or.jp/link/ui/2023252494
• Data Provider (Database): 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• Original Data Provider (Database): Japan Link Center; https://japanlinkcenter.org/top; 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp
• Bibliographic ID (NDL): 032834787; http://id.ndl.go.jp/bib/032834787; 13120768; http://id.ndl.go.jp/bib/13120768